The Kunitz-3 domain of TFPI-α is required for protein S-dependent enhancement of factor Xa inhibition

Blood

Volumn 116, Issue 8, 2010, Pages 1344-1351

  Ndonwi, Matthew ^a   Tuley, Elodee A ^a   Broze Jr , George J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; PROTEIN S; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR ALPHA; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; INHIBITION KINETICS; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN ISOLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SURFACE PLASMON RESONANCE; WESTERN BLOTTING; WILD TYPE;

EID: 77956547096     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-10-246686     Document Type: Article

References (37)

1. Leytus SP, Foster DC, Kurachi K, Davie EW. Gene for human factor X: a blood coagulation factor whose gene organization is essentially identical with that of factor IX and protein C. Biochemistry. 1986;25(18):5098-5102. (Pubitemid 17016521)
2. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry. 1991;30(43):10363-10370.
3. Mann KG, Nesheim ME, Church WR, Haley P, Krishnaswamy S. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood. 1990;76(1):1-16.
4. Jackson CM, Nemerson Y. Blood coagulation. Annu Rev Biochem. 1980;49:765-811.
5. Broze GJ Jr, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood. 1988;71(2):335-343.
6. Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci U S A. 1990;87(22):8869-8873. (Pubitemid 120007610)
7. Wun TC, Kretzmer KK, Girard TJ, Miletich JP, Broze GJ Jr. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem. 1988;263(13):6001-6004.
8. Baugh RJ, Broze GJ Jr, Krishnaswamy S. Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor. J Biol Chem. 1998;273(8):4378-4386.
9. Girard TJ, Warren LA, Novotny WF, et al. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature. 1989;338(6215):518-520.
10. Petersen LC, Bjørn SE, Olsen OH, et al. Inhibitory properties of separate recombinant Kunitz-type-protease-inhibitor domains from tissue-factor-pathway inhibitor. Eur J Biochem. 1996;235(1-2):310-316.
11. Piro O, Broze G Jr. Role for the Kunitz-3 domain of tissue factor pathway inhibitor-alpha in cell surface binding. Circulation. 2004;110(23):3567-3572.
12. Hackeng TM, Seré KM, Tans G, Rosing J. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci U S A. 2006;103(9):3106-3111. (Pubitemid 43346432)
13. Castoldi E, Hackeng TM. Regulation of coagulation by protein S. Curr Opin Hematol. 2008;15(5):529-536.
14. Broze GJ Jr, Lange GW, Duffin KL, MacPhail L. Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coagul Fibrinolysis. 1994;5(4):551-559.
15. Wesselschmidt R, Likert K, Girard T, Wun T, Broze GJ Jr. Tissue factor pathway inhibitor: the carboxy terminus is required for optimal inhibition of factor Xa. Blood. 1992;79(8):2004-2010.
16. Girard TJ, Warren LA, Novotny WF, Bejcek BE, Miletich JP, Broze GJ Jr. Identification of the 1.4 kb and 4.0 kb messages for the lipoprotein associated coagulation inhibitor and expression of the encoded protein. Thromb Res. 1989;55(1):37-50.
17. Wesselschmidt R, Likert K, Huang Z, MacPhail L, Broze GJ Jr. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. Blood Coagul Fibrinolysis. 1993;4(5):661-669. (Pubitemid 23343388)
18. Diaz-Collier JA, Palmier MO, Kretzmer KK, et al. Refold and characterization of tissue factor pathway inhibitor expressed in Escherichia coli. Thromb Haemost. 1994;71(3):339-346.
19. Zhang J, Piro O, Lu L, Broze GJ Jr. Glycosyl phosphatidylinositol anchorage of tissue factor pathway inhibitor. Circulation. 2003;108(5):623-627. (Pubitemid 36961180)
20. Warshawsky I, Broze GJ Jr, Schwartz AL. The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor. Proc Natl Acad Sci U S A. 1994;91(14):6664-6668.
21. Morrison JF, Walsh CT. The behavior and significance of slow-binding enzyme inhibitors. Adv Enzymol Relat Areas Mol Biol. 1988;61:201-301.
22. Huang Z, Wun T, Broze GJ. Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J Biol Chem. 1993;268(36):26950-26955. (Pubitemid 24006403)
23. Underwood MC, Zhong D, Mathur A, Heyduk T, Bajaj SP. Thermodynamic linkage between the S1 site, the Na+ site and the Ca2+ site in the protease domain of human blood coagulation factor Xa. J Biol Chem. 2000;275(47):36876- 36884.
24. Halfman CJ. Concentrations of binding protein and labeled analyte that are appropriate for measuring at any analyte concentration range in radioimmunoassays. Methods Enzymol. 1981;74:481-508.
25. Johnsson B, Löfås S, Lindquist G. Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors. Anal Biochem. 1991;198(2):268-277.
26. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227(5259):680-685.
27. Mast AE, Broze GJ Jr. Physiological concentrations of tissue factor pathway inhibitor do not inhibit prothrombinase. Blood. 1996;87(5):1845-1850.
28. Heeb MJ, Rosing J, Bakker HM, Fernandez JA, Tans G, Griffin JH. Protein S binds to and inhibits factor Xa. Proc Natl Acad Sci U S A. 1994;91(7):2728- 2732.
29. Seré KM, Janssen MP, Willems GM, Tans G, Rosing J, Hackeng TM. Purified protein S contains multimeric forms with increased APC-independent anticoagulant activity. Biochemistry. 2001;40(30):8852-8860.
30. Pauls JED, Hockin MF, Long GL, Mann KG. Selfassociation of human protein S. Biochemistry. 2000;39(18):5468-5473.
31. Mann KG. Analyses of protein S function. Blood. 2005;106(5):1884-1885.
32. Heeb MJ, Schuck P, Xu X. Protein S multimers and monomers each have direct anticoagulant activity. J Thromb Haemost. 2006;4(2):385-391.
33. Heeb MJ, Radtke KP, Fernandez JA, Tonnu L. Plasma contains protein S monomers and multimers with similar direct anticoagulant activity. J Thromb Haemost. 2006;4(10):2215-2222. (Pubitemid 44400301)
34. Ndonwi M, Broze GJ Jr. Protein S enhances the tissue factor pathway inhibitor inhibition of factor Xa but not its inhibition of factor VIIa-tissue factor. J Thromb Haemost. 2008;6(6):1044-1046.
35. Yegneswaran S, Hackeng TM, Dawson PE, Griffin JH. The thrombin-sensitive region of protein S mediates phospholipid-dependent interaction with factor Xa. J Biol Chem. 2008;283(48):33046-33052.
36. Duckers C, Simioni P, Spiezia L, et al. Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. Blood. 2008;112(9):3615-3623.
37. Castoldi E, Simioni P, Tormene D, Rosing J, Hackeng TM. Hereditary and acquired protein S deficiencies are associated with low TFPI levels in plasma. J Thromb Haemost. 2010;8(2):294-300.